Index

A
ACVR2B, mutations in heterotaxy, 247
ADCL, see Autosomal-dominant cutis laxa
Alagille syndrome,
clinical features, 217
JAG1 mutation detection,
cardiovascular manifestations, 218
conformation-sensitive gel electrophoresis, 220, 221, 225, 227, 230
fluorescence in situ hybridization, 223–225, 230
materials, 222, 223, 228–230
mutation types, 220
overview, 9, 10, 220, 221
polymerase chain reaction, 225, 230
sequencing, 230, 231
Amplification refractory mutation system (ARMS) assay, ZIC3 mutation screening in heterotaxy, 253, 255
Andersen syndrome, see Long QT syndrome
ANKB, mutation in long QT syndrome, 69
ARMS assay, see Amplification refractory mutation system assay
ASD, see Atrial septal defect
Atrial septal defect (ASD), see also specific diseases,
cardiogenesis, 20
diseases, 22–24
epidemiology, 19, 20
GATA-4 mutations, 28, 29
NKX2.5 mutations, 26–28
preimplantation genetic diagnosis, clinical follow-up, 35, 36
in vitro fertilization and blastomere biopsy, 34
materials, 33, 34
overview, 2, 3, 33
restriction fragment length polymorphism analysis, 35, 36
TBX5 mutation detection, 34, 35
Autosomal-dominant cutis laxa (ADCL), clinical features, 130, 131
ELN gene mutation analysis,
denaturing high-performance liquid chromatography,
polymerase chain reaction, 143, 145, 154, 155
principles, 144
running conditions, 145
genotyping,
fluorescent genotyping, 150
microsatellite markers, 149
nonfluorescent genotyping, 149, 150
single nucleotide polymorphisms, 149
lesion types, 132, 133
materials, 133–136
overview, 7, 130, 131, 136, 137
partial deletion and translocation analysis, 148
reverse transcriptase-polymerase chain reaction of transcripts in cultured fibroblasts,
amplification reaction, 154
applications, 150
first-strand cDNA synthesis, 153
RNA preparation, 152, 153
sequencing, 145, 146, 148
single-strand conformation polymorphism analysis,
gel electrophoresis, 140, 142, 144
polymerase chain reaction, 139–142
principles, 137–139
silver staining of gels, 144
AVSD, see Atrioventricular septal defect
epidemiology, 19, 31
preimplantation genetic diagnosis,
clinical follow-up, 35, 36
in vitro fertilization and blastomere biopsy, 34
materials, 33, 34
overview, 2, 3, 33
restriction fragment length polymorphism analysis, 35, 36
TBX5 mutation detection, 34, 35
Brugada syndrome, clinical features, 72
clinical genetics, 72
genetic analysis, denaturing high-performance liquid chromatography, anticipated results, 64
polymerase chain reaction of target sequences, 60, 74
principles, 59, 60
running conditions, 60–62, 74, 75
materials, 58, 59, 73, 74
overview, 4
sequencing, anticipated results, 64
cycle sequencing reaction, 63, 64
overview, 62, 63
primer labeling, 63
template preparation, 63
SCN5A mutations, 72

CardioChip, see DNA microarray
Cardiomyopathy, clinical features, 257, 258
DNA microarray analysis, see DNA microarray
forms, 157, 257
pediatric cardiomyopathy, incidence, 258
etiologies, 258
genetics, 258
denaturing high-performance liquid chromatography of gene mutations, amplification product denaturation and reannealing, 264
DNA extraction, 263
instrumentation, 259, 265
interpretation, 265
materials, 259
overview, 11, 12
polymerase chain reaction, 263, 264
primer design, 263
principles, 259–261
running conditions, 264, 265, 267
target sequence selection, 262, 263, 267
sequencing of gene mutations, 265
Catecholaminergic polymorphic ventricular tachycardia (CPVT),
CASQ2 mutations, 172, 173
clinical features, 73, 171, 172
genetic analysis, denaturing high-performance liquid chromatography, analysis, 179, 181, 182
anticipated results, 64
polymerase chain reaction of target sequences, 60, 74, 176, 182
principles, 59, 60
running conditions, 60–62, 74, 75, 176, 177, 182
materials, 58, 59, 73, 74, 173, 174, 181
overview, 4, 8
sequencing, analysis, 77, 179, 182
anticipated results, 64
BigDye sequencing, 175, 181
cycle sequencing reaction, 63, 64
overview, 62, 63
polymerase chain reaction and electrophoresis of products, 175, 176, 181
primer labeling, 63
template preparation, 63
KCNJ2 mutations, 173
RyR2 mutations, 73, 172
Chromosome 22q11 deletion syndrome, see DiGeorge syndrome; Velocardiofacial syndrome
Conformation-sensitive gel electrophoresis (CSGE), JAG1 mutation detection in Alagille syndrome, 220, 221, 225, 227, 230
CPVT, see Catecholaminergic polymorphic ventricular tachycardia
CRELD1, atrioventricular septal defect mutations, 32
CSGE, see Conformation-sensitive gel electrophoresis

Denaturing high-performance liquid chromatography (DHPLC), cardiac arrhythmia gene mutation screening, anticipated results, 64
polymerase chain reaction of target sequences, 60, 74
principles, 59, 60
running conditions, 60–62, 74, 75
catecholaminergic polymorphic ventricular tachycardia genetic analysis, analysis, 179, 181, 182
anticipated results, 64
polymerase chain reaction of target
sequences, 60, 74, 176, 182
principles, 59, 60
running conditions, 60–62, 74, 75,
176, 177, 182
ELN gene mutation analysis,
Marfan syndrome FBN1 mutations,
85–91
Noonan syndrome PTPN11
mutations, 101, 102
polymerase chain reaction, 143, 145,
154, 155
principles, 144
running conditions, 145
Marfan syndrome FBN1 mutations,
genomic DNA isolation, messenger
RNA isolation, and cDNA
production, 84, 85
materials, 83, 84
overview, 4, 5
polymerase chain reaction, 85–91
principles, 82, 83
running conditions, 85, 87, 94
sample preparation, 83, 84, 87, 94
sequencing, 87
Noonan syndrome PTPN11 mutation
analysis with WAVE,
Analysis Page entries, 106, 110
DNA Page entries, 104, 105
Injection Page entries, 105, 106
materials, 98, 100, 101, 106
mutation types, 99
overview, 5, 6, 97, 98
polymerase chain reaction, 101, 102
running conditions, 102, 103, 106,
108–110
pediatric cardiomyopathy gene mutations,
amplification product denaturation
and reannealing, 264
DNA extraction, 263
instrumentation, 259, 265
interpretation, 265
materials, 259
overview, 11, 12
polymerase chain reaction, 263, 264
primer design, 263
principles, 259–261
running conditions, 264, 265, 267
target sequence selection, 262, 263, 267
DGS, see DiGeorge syndrome
DHPLC, see Denaturing high-performance
liquid chromatography

DiGeorge syndrome (DGS),
chromosome 22q11 deletions,
characteristics, 45, 46, 49
diagnostic testing,
control probe, 48–50
cytogenetic analysis, 47
fluorescence in situ hybridization,
47, 49
materials, 48
microsatellite markers, 50, 51
prenatal resting indications, 47
quantitative polymerase chain
reaction, 51
overview, 3, 4
clinical features, 30, 43–45
TBX1 mutations, 30, 50
DNA microarray,
aplications, 158, 160, 233, 234
CardioChip analysis of cardiomyopathy,
data processing, 164–166
materials, 161, 162
microarray construction, 162, 163
overview, 7, 8, 161
polymerase chain reaction products, 162
probe labeling and hybridization,
163–165
reverse transcriptase–polymerase chain
reaction verification, 164, 166
scanning, 164, 165
historical perspective, 158
platforms, 159
principles, 159, 160, 234, 235
tetralogy of Fallot analysis,
array selection, 237, 238
data normalization and statistical
analysis, 239, 241, 242, 243, 245
experimental design, 238–241
hybridization, 239, 245
materials, 235, 236
overview, 10, 11, 234, 235
RNA isolation, cDNA synthesis, and
labeling, 239, 245
cample selection, 237, 245

E
EGF-CFC, mutations in heterotaxy, 247
Elastin,
ELN gene,
mutations, see Autosomal-dominant
cutis laxa; Supravalvular aortic
stenosis
structure, 130
synthesis, 129, 130
tissue distribution, 129
Ellis–van Crevald syndrome,
clinical features, 29

EVC genes and mutations, 29, 30

ELN, see Elastin

F

FA, see Friedreich ataxia

FBN1, see Marfan syndrome

FISH, see Fluorescence in situ hybridization

Fluorescence in situ hybridization (FISH),
chromosome 22q11 deletion syndrome
diagnostics, 47, 49

JAG1 mutation detection in Alagille
syndrome, 223–225, 230

Williams–Beuren syndrome diagnosis,
chromosome counterstaining and
banding, 125, 126
deletion detection, 127
denaturation, 124
hybridization, 124
imaging, 126, 128

immunodetection, 125, 128
inversion detection, 127
materials, 114, 117, 118
overview, 6, 7, 113, 114
probe preparation,
biotin labeling, 122, 123
clone selection, 120
combination labeling, 123
common deletion probe, 120
digoxigenin labeling, 122
genomic clone propagation,
amplification and DNA
isolation, 121, 122
inversion probes, 121, 127, 128
larger deletion probes, 121
sizing of labeled fragments, 123
smaller deletion probes, 121
Spectrum Green labeling, 123
target DNA preparation,
lymphoblastoid cell line culture
and harvest, 119, 120
peripheral blood lymphocyte
culture and harvest, 119
slide preparation, 120
washing, 125

Frataxin, see Friedreich ataxia

Friedreich ataxia (FA),
animal models, 204, 405
clinical presentation, 198–200
epidemiology, 198
frataxin gene mutations, 200, 201
laboratory findings, 200

molecular diagnostics,
materials, 206
overview, 9, 205, 206
point mutation detection, 208–211
polymerase chain reaction, 207,
208, 210
sequencing, 208, 210
Southern blot, 208, 210
pathogenesis, 201, 203, 204
prognosis, 200
treatment prospects, 205

G–H

GATA-4,
cardiogenesis role, 28, 29
congenital heart malformations and
mutations, 28, 29
Heart failure, see Cardiomyopathy

Heterotaxy,
definition, 247
gene mutations, 247

ZIC3 mutation screening,
amplification product purification and
gel electrophoresis, 251, 252, 255
controls for polymorphisms,
amplification refractory mutation
system assay, 253, 255
restriction fragment length
polymorphism, 253, 255
genomic DNA preparation, 248
materials, 248
overview, 11, 247, 248
polymerase chain reaction, 251,
254, 255
primer design, 248, 249, 254

Hey genes, cardiogenesis role, 31

Holt–Oram syndrome (HOS),
clinical features, 21, 25
epidemiology, 21
gene expression, 26

TBX5 mutations, 25

HOS, see Holt–Oram syndrome

I–K

Ivemark syndrome, atrioventricular septal
defects, 33

JAG1, see also Alagille syndrome,
congenital heart disease mutations, 218, 219
protein function, 219
vascular manifestations of mutations, 219
Jervell and Lange-Nielson syndrome, see
Long QT syndrome

KCNE1, mutation in long QT syndrome, 69–71
KCNE2, mutation in long QT syndrome, 70

KCNH2, mutation in long QT syndrome, 67, 68

KCNJ2, catecholaminergic polymorphic ventricular tachycardia mutations, 173

long QT syndrome mutations, 71, 173

KCNQ1, mutation in long QT syndrome, 66, 70, 71

L

LEFTYA, mutations in heterotaxy, 247

LOH, see Loss of heterozygosity

Long QT syndrome (LQTS),

Andersen syndrome gene mutations, 71, 72, 173

clinical description, 65

genetic analysis,

denaturing high-performance liquid chromatography,

anticipated results, 64

polymerase chain reaction of target sequences, 60, 74

principles, 59, 60

running conditions, 60–62, 74, 75

materials, 58, 59, 73, 74

overview, 4

sequencing,

anticipated results, 64

cycle sequencing reaction, 63, 64

overview, 62, 63

primer labeling, 63

template preparation, 63

genetics, 65, 66

Jervell and Lange-Nielson syndrome

gene mutations, 70, 71

Romano–Ward syndrome gene identification,

ANKB, 69

KCNE1, 69, 70

KCNE2, 70

KCNH2, 67, 68

KCNQ1, 66

SCN5A, 68, 69

treatment, 70

Loss of heterozygosity (LOH),

microsatellite markers analysis in tuberous sclerosis complex,

autoradiography, 190, 191, 194

denaturing gel electrophoresis, 189, 190, 195

interpretation, 192

microsatellite markers, 186

LQTS, see Long QT syndrome

M

Marfan syndrome (MFS), clinical features, 81, 82

FBN1, denaturing high-performance liquid chromatography analysis of mutations, genomic DNA isolation, messenger RNA isolation and cDNA production, 84, 85

materials, 83, 84

overview, 4, 5

polymerase chain reaction, 85–91

principles, 82, 83

running conditions, 85, 87, 94

sample preparation, 83, 84, 87, 94

sequencing, 87

genotype–phenotype correlations, 82

protein function, 82

structure, 82

MFS, see Marfan syndrome

Microsatellite markers,

ELN gene mutation analysis, 149

loss of heterozygosity analysis in tuberous sclerosis complex, autoradiography, 190, 191, 194

denaturing gel electrophoresis, 189, 190, 195

interpretation, 192

microsatellite markers, 186

N

NKX2.5, cardiogenesis role, 27, 28

congenital heart malformations and mutations, 26–28

Noonan syndrome, atrioventricular septal defects, 32

clinical features, 97

PTPN11 mutation analysis with WAVE denaturing high-performance liquid chromatography,

Analysis Page entries, 106, 110

DNA Page entries, 104, 105

Injection Page entries, 105, 106

materials, 98, 100, 101, 106

mutation types, 99

overview, 5, 6, 97, 98

polymerase chain reaction, 101, 102

running conditions, 102, 103, 106, 108–110
P
PCR, see Polymerase chain reaction
Pediatric cardiomyopathy, see Cardiomyopathy
Polymerase chain reaction (PCR), see also Reverse transcriptase-polymerase chain reaction,
Brugada syndrome target sequences, 60, 74
CardioChip analysis of cardiomyopathy, 162
catecholaminergic polymorphic ventricular tachycardia genes, 175, 176, 181
chromosome 22q11 deletions, 51
denaturing high-performance liquid chromatography target sequences, cardiac arrhythmia gene mutation screening, 60, 74
catecholaminergic polymorphic ventricular tachycardia, 60, 74, 176, 182
ELN gene, 143, 145, 154, 155
pediatric cardiomyopathy gene mutations, 263, 264
ELN gene mutation analysis, 139–142
frataxin gene mutations in Friedreich ataxia, 207, 208, 210
JAG1 mutation detection in Alagille syndrome, 225, 230
TSC1/2 mutation detection, 189, 193, 194
ZIC3 mutation screening in heterotaxy, 251, 254, 255
Polymorphic ventricular tachycardia, see Catecholaminergic polymorphic ventricular tachycardia
PTPN11, see Noonan syndrome
R
Restriction fragment length polymorphism (RFLP),
preimplantation genetic diagnosis, 35, 36
ZIC3 mutation screening in heterotaxy, 253, 255
Reverse transcriptase-polymerase chain reaction (RT-PCR),
CardioChip verification, 164, 166
ELN transcripts in cultured fibroblasts, amplification reaction, 154
applications, 150
first-strand cDNA synthesis, 153
RNA preparation, 152, 153
RFLP, see Restriction fragment length polymorphism
Rhabdomyoma, see Tuberous sclerosis complex
Romano–Ward syndrome, see Long QT syndrome
RT-PCR, see Reverse transcriptase-polymerase chain reaction
RyR2, polymorphic ventricular tachycardia mutations, 73, 172
S
SCN5A,
Brugada syndrome mutations, 72
long QT syndrome mutations, 68, 69
Single nucleotide polymorphisms (SNPs),
genotyping in supravalvular aortic stenosis, 149
Single-strand conformation polymorphism (SSCP),
ELN gene mutation analysis,
gel electrophoresis, 140, 142, 144
polymerase chain reaction, 139–142
principles, 137–139
silver staining of gels, 144
tuberous sclerosis complex analysis, 191, 194
SNPs, see Single nucleotide polymorphisms
Southern blot, frataxin defect detection in Friedreich ataxia, 208, 210
SSCP, see Single-strand conformation polymorphism
Sudden cardiac death, incidence, 57
Supravalvular aortic stenosis (SVAS), clinical features, 13
ELN gene mutation analysis,
denaturing high-performance liquid chromatography,
polymerase chain reaction, 143, 145, 154, 155
principles, 144
running conditions, 145
genotyping,
fluorescent genotyping, 150
microsatellite markers, 149
nonfluorescent genotyping, 149, 150
single nucleotide polymorphisms, 149
lesion types, 132, 133
materials, 133–136
overview, 7, 130, 131, 136, 137
partial deletion and translocation analysis, 148
reverse transcriptase-polymerase chain reaction of transcripts in cultured fibroblasts,
amplification reaction, 154
applications, 150
first-strand cDNA synthesis, 153
RNA preparation, 152, 153
sequencing, 145, 146, 148
single-strand conformation
polymorphism analysis, 140, 142, 144
polymerase chain reaction, 139–142
principles, 137–139
silver staining of gels, 144
SVAS, see Supravalvular aortic stenosis

T

TBX1,
DiGeorge syndrome mutations, 30, 50
sequencing, 50

TBX5,
cardiogenesis role, 25, 26
Holt–Oram syndrome mutations, 25
preimplantation genetic diagnosis, 34

Tetralogy of Fallot (TOF),
DNA microarray analysis,
array selection, 237, 238
data normalization and statistical
analysis, 239, 241, 242, 243, 245
experimental design, 238–241
hybridization, 239, 245
materials, 235, 236
overview, 10, 11, 234, 235
RNA isolation, cDNA synthesis, and
labeling, 239, 245
sample selection, 237, 245
molecular pathogenesis, 235

TOF, see Tetralogy of Fallot

TSC, see Tuberous sclerosis complex

Tuberous sclerosis complex (TSC),
clinical features, 185

TSC1/2 mutation detection in archival
tissue specimens,
DNA extraction, 187–189, 193
gene structures, 186
laser capture microdissection, 188, 189, 193
loss of heterozygosity analysis,
autoradiography, 190, 191, 194
denaturing gel electrophoresis, 189, 190, 195
interpretation, 192
microsatellite markers, 186
materials, 186, 187
overview, 8, 9, 186

polymerase chain reaction, 189, 193, 194
sequencing, 191–194
single-strand conformational
polymorphism analysis, 191, 194
tumor suppressor gene mutations, 185, 186

Tumor suppressor genes, see Tuberous
sclerosis complex

VCFS, see Velocardiofacial syndrome

Velocardiofacial syndrome (VCFS),
chromosome 22q11 deletions,
characteristics, 45, 46, 49
diagnostic testing,
control probe, 48–50
cytogenetic analysis, 47
fluorescence in situ hybridization,
47, 49
materials, 48
microsatellite markers, 50, 51
prenatal resting indications, 47
quantitative polymerase chain
reaction, 51
overview, 3, 4
clinical features, 30, 44, 45

Ventricular septal defect (VSD), see also
specific diseases,
cardiogenesis, 20
diseases, 22–24
epidemiology, 19
GATA-4 mutations, 28, 29
preimplantation genetic diagnosis,
clinical follow-up, 35, 36
in vitro fertilization and blastomere
biopsy, 34
materials, 33, 34
overview, 2, 3, 33
restriction fragment length
polymorphism analysis, 35, 36

TBX5 mutation detection, 34, 35

Ventricular tachycardia, see Catecholaminergic
polymorphic ventricular tachycardia

VSD, see Ventricular septal defect

W

WAVE, see Denaturing high-performance
liquid chromatography

WBS, see Williams–Beuren syndrome

Williams–Beuren syndrome (WBS),
clinical features, 113
epidemiology, 113
fluorescence in situ hybridization diagnosis,
chromosome counterstaining and banding, 125, 126
deletion detection, 127
denaturation, 124
hybridization, 124
imaging, 126, 128
immunodetection, 125, 128
inversion detection, 127
materials, 114, 117, 118
overview, 6, 7, 113, 114
probe preparation,
  biotin labeling, 122, 123
  clone selection, 120
  combination labeling, 123
  common deletion probe, 120
digoxigenin labeling, 122
genomic clone propagation,
  amplification and DNA isolation, 121, 122
inversion probes, 121, 127, 128
larger deletion probes, 121
sizing of labeled fragments, 123
smaller deletion probes, 121
Spectrum Green labeling, 123
target DNA preparation,
  lymphoblastoid cell line culture and harvest, 119, 120
  peripheral blood lymphocyte culture and harvest, 119
  slide preparation, 120
  washing, 125
supravalvular aortic stenosis, see Supravalvular aortic stenosis
Z
  ZIC3, heterotaxy mutation screening,
    amplification product purification and gel electrophoresis, 251, 252, 255
    controls for polymorphisms,
      amplification refractory mutation system assay, 253, 255
      restriction fragment length polymorphism, 253, 255
    genomic DNA preparation, 248
    materials, 248
    overview, 11, 247, 248
    polymerase chain reaction, 251, 254, 255
    primer design, 248, 249, 254